Journal ArticleOPEN ACCESS

Entecavir‐induced neutropenia in an adult living donor liver transplant recipient: Successful conversion to tenofovir alafenamide

  • Lim I
  • Yurttaş N
  • Ayer M
  • et al.
Clinical Case Reports (2023) 11(8)
DOI: 10.1002/ccr3.7741
N/ACitations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

At 22 weeks post‐transplantation for HBV‐related cirrhosis, an adult woman developed neutropenia which was aggravated by COVID‐19 (ANC 0.4 × 10 9 /L). Covid resolution and all “conventional” modifications were ineffective. Success within 2 weeks was achieved by switching entecavir to tenofovir alafenamide. A step‐by‐step judicious approach to post‐transplant neutropenia is vital.

Cite

CITATION STYLE

APA

Lim, I. V., Yurttaş, N. Ö., Ayer, M., Poturoğlu, Ş., Kınacı, E., & Özden, İ. (2023). Entecavir‐induced neutropenia in an adult living donor liver transplant recipient: Successful conversion to tenofovir alafenamide. Clinical Case Reports, 11(8). https://doi.org/10.1002/ccr3.7741

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free